Geographic Atrophy Market Report 2025-2035

Overall world revenue for the Geographic Atrophy Market: In terms of value the market will surpass US$7.40 billion in 2025, the work calculates. The publisher predicts strong revenue growth through to 2035. The work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

The Geographic Atrophy Market Report 2025-2035 (Including Impact of U.S. Trade Tariffs): This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Growing Prevalence of Geographic Atrophy

Geographic atrophy (GA) is closely linked with ageing, predominantly affecting people aged 60 and above. As a result, population ageing stands out as one of the strongest drivers of future demand. A 2024 Journal of the American Medical Association (JAMA) study projects that global cases of age-related macular degeneration will rise from 196 million today to 288 million by 2040.

As prevalence rises, the need for effective therapies is intensifying. Biopharmaceutical companies are responding by advancing treatments designed with greater durability, improved safety, and enhanced usability for elderly patients. Uptake of recently approved drugs such as pegcetacoplan and avacincaptad pegol has already been strong across high-income regions, where ageing populations are expanding fastest. Beyond clinical impact, the demographic shift also represents a commercial imperative: drug makers must adapt by designing accessible therapies and building patient support programmes to serve a growing, vulnerable population segment.

Limited Efficacy of Current Therapies is Hindering the Market Growth

The therapeutic impact of currently approved complement inhibitors for geographic atrophy (GA) remains the subject of ongoing debate. While these drugs have demonstrated the ability to slow lesion growth, the effect is modest and does not consistently translate into meaningful improvements in functional vision. Results from the pivotal OAKS and DERBY Phase 3 trials showed average reductions in GA lesion enlargement of around 16-22% over one to two years, with clearer separation from sham groups emerging over time. However, improvements in key functional outcomes, such as best-corrected visual acuity, were not reliably achieved.

Safety concerns further complicate adoption. Post-marketing surveillance and registry data have reported clusters of intraocular inflammation and other retinal inflammatory events in treated patients, prompting tighter monitoring requirements and more selective patient eligibility. Coupled with the ongoing burden of frequent intravitreal injections, these factors have dampened enthusiasm for broad use.

In practice, current therapies provide meaningful yet limited benefits, with uptake largely confined to carefully chosen patient populations. For the wider retinal community, stronger long-term data on safety and functional outcomes remain essential before these treatments can achieve mainstream adoption.

What would be the Impact of US Trade Tariffs on the Global Geographic Atrophy Market ?

U.S. trade tariffs have the potential to indirectly influence the global market for geographic atrophy (GA) therapies by raising production costs for treatments and their delivery devices. While finished biopharmaceuticals such as GA drugs are often exempt from high tariffs due to their medical necessity, the upstream components essential to their manufacture-such as sterile fill-finish equipment, specialised glass vials, and injection devices-are frequently sourced from tariff-affected countries. Any increase in costs for these inputs drives up overall production expenses, which can, in turn, translate into higher treatment prices. Given that GA therapies already carry premium price points, even marginal cost increases risk complicating payer negotiations, restricting patient access, and slowing adoption in cost-sensitive healthcare systems.

The implications extend well beyond the U.S. Pharmaceutical companies typically operate integrated supply chains spanning multiple regions, and while large multinationals with diversified sourcing can absorb or offset tariff risks, smaller biotech firms dependent on single-source suppliers may face significant margin pressures. For these companies, partnerships with larger players may become a necessity. Over time, persistent tariffs could prompt more investment in localised manufacturing and supplier diversification, reshaping competitive dynamics and altering how quickly GA therapies can scale globally.

In response, companies may fast-track investments in domestic production sites or shift parts of their supply chains to tariff-neutral regions to mitigate exposure. This restructuring could elevate the role of emerging markets such as Asia Pacific and Latin America as alternative manufacturing hubs. However, such transitions demand considerable capital and time, potentially slowing innovation or delaying the availability of new therapies in the short term. In the longer run, the interaction between tariffs, localisation, and global demand is likely to redefine how GA treatments are priced, distributed, and adopted worldwide.

Key Questions Answered

How is the geographic atrophy market evolving?
What is driving and restraining the geographic atrophy market?
How will each geographic atrophy submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
How will the market shares for each geographic atrophy submarket develop from 2025 to 2035?
What will be the main driver for the overall market from 2025 to 2035?
Will leading geographic atrophy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
Who are the leading players and what are their prospects over the forecast period?
What are the geographic atrophy projects for these leading companies?
How will the industry evolve during the period between 2025 and 2035? What are the implications of geographic atrophy projects taking place now and over the next 10 years?
Is there a greater need for product commercialisation to further scale the geographic atrophy market?
Where is the geographic atrophy market heading and how can you ensure you are at the forefront of the market?
What are the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the geographic atrophy market today, and over the next 10 years:

This 323-page report provides 130 tables and 190 charts/graphs exclusively to you.
The report highlights key lucrative areas in the industry so you can target them - NOW.
It contains in-depth analysis of global, regional and national sales and growth.
It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2035 and other analysis reveal commercial prospects

In addition to revenue forecasting to 2035, the new study provides you with recent results, growth rates, and market shares.
You will find original analysis, with business outlooks and developments.
Discover qualitative analysis (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising geographic atrophy prices and recent developments.

Segments Covered in the Report

Type

Focal GA
Multifocal GA
Confluent GA

Drugs

Pegcetacoplan (SYFOVRE)
Avacincaptad pegol (IZERVAY)
Tinlarebant (LBS-008)
Gildeuretinol (ALK-001)
Others

Route of Administration

Intravitreal Route
Intravenous Route
Others

Age Group

Below 60 Years
Above 60 Years
Above 70 Years

Distribution Channel

Hospital Pharmacies
Retail Pharmacies
E-Commerce Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 19 leading national markets:

North America

U.S.
Canada

Europe

Germany
UK
France
Italy
Spain
Russia
Netherlands
Denmark
Rest of Europe

Asia Pacific

Japan
China
India
Australia
South Korea
Rest of Asia Pacific

Latin America

Brazil
Mexico
Rest of Latin America

MEA

GCC
South Africa
Rest of MEA

The report also includes profiles for some of the leading companies in the Geographic Atrophy Market, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

Alkeus Pharmaceuticals, Inc.
Annexon, Inc.
Apellis Pharmaceuticals
Astellas Pharma Inc.
AstraZeneca
Aviceda Therapeutics
Bausch + Lomb
Belite Bio‚Ñ¢ Inc.
Boehringer Ingelheim International GmbH
Cognition Therapeutics
F. Hoffmann-La Roche Ltd.
Ionis Pharmaceuticals
Johnson & Johnson
Santen Pharmaceutical Co., Ltd.
Stealth BioTherapeutics

How will the Geographic Atrophy Market report help you?

In summary, the 320+ page report provides you with the following knowledge:

Revenue forecasts to 2035 for Geographic Atrophy Market, with forecasts for type, drugs, route of administration, age group, and distribution channel, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
Revenue forecasts to 2035 for five regional and 19 key national markets - See forecasts for the Geographic Atrophy Market in North America, Europe, Asia Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Geographic Atrophy Market.

Find quantitative and qualitative analysis with independent predictions. Receive information that only this report contains, staying informed with invaluable business intelligence.

1 Report Overview

1.1 Objectives of the Study
1.2 Introduction to Geographic Atrophy Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About the Publisher

2 Executive Summary

3 Market Overview

3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Expanding Clinical Trial Pipeline for GA Treatments
3.3.1.2 Rising Ageing Population Worldwide is Driving the Demand for GA Drugs
3.3.1.3 Growing Prevalence of Geographic Atrophy
3.3.1.4 Approval of Novel and Advanced Drugs
3.3.2 Market Restraining Factors
3.3.2.1 High Treatment Costs
3.3.2.2 Limited Efficacy of Current Therapies
3.3.2.3 Regulatory and Reimbursement Hurdles Across Regions
3.3.2.4 Low Awareness in Emerging and Low-income Markets
3.3.3 Market Opportunities
3.3.3.1 Development of Oral and Less Invasive Therapies
3.3.3.2 Growth Potential in Emerging Markets including Asia Pacific and Latin America
3.3.3.3 Strategic M&A and Partnerships Among Market Players for Faster Innovation and Expansion
3.4 U.S. Tariffs: What's the Impact on Global Geographic Atrophy Market?
3.4.1 Overview
3.4.2 V-Shaped Recovery Scenario
3.4.2.1 Why V-Shaped Recovery?
3.4.2.2 Impact from Tariffs
3.4.2.3 Market Dynamics and Demand Recovery
3.4.2.4 Policy and Funding Support
3.4.2.5 Timeframe for Recovery
3.4.3 U-Shaped Recovery Scenario
3.4.3.1 Why U-Shaped Recovery?
3.4.3.2 Impact from Tariffs
3.4.3.3 Market Dynamics and Demand Recovery
3.4.3.4 Policy and Funding Support
3.4.3.5 Timeframe for Recovery
3.4.4 L Shaped Recovery Scenario
3.4.4.1 Why L-Shaped Recovery?
3.4.4.2 Impact from Tariffs
3.4.4.3 Market Dynamics and Demand Recovery
3.4.4.4 Policy and Funding Support
3.4.4.5 Timeframe for Recovery
3.4.5 What Strategic Considerations Should Clients Factor into Their Near-term (2025-2030) and Long-term (2025-2035) Planning?
3.4.6 Impact of U.S. and China Trade War on Geographic Atrophy Market
3.5 Regulatory Framework
3.6 Emerging Markets and Megatrends
3.7 Porter's Five Forces Analysis
3.7.1 Bargaining Power of Suppliers
3.7.2 Bargaining Power of Buyers
3.7.3 Competitive Rivalry
3.7.4 Threat of Substitutes
3.7.5 Threat of New Entrants
3.8 PEST Analysis

4 Geographic Atrophy Market Analysis by Type

4.1 Key Findings
4.2 Type Segment: Market Attractiveness Index
4.3 Geographic Atrophy Market Size Estimation and Forecast by Type
4.4 Focal GA
4.4.1 Market Size by Region, 2025-2035 (US$ Million)
4.4.2 Market Share by Region, 2025 & 2035 (%)
4.5 Multifocal GA
4.5.1 Market Size by Region, 2025-2035 (US$ Million)
4.5.2 Market Share by Region, 2025 & 2035 (%)
4.6 Confluent GA
4.6.1 Market Size by Region, 2025-2035 (US$ Million)
4.6.2 Market Share by Region, 2025 & 2035 (%)

5 Geographic Atrophy Market Analysis by Drugs

5.1 Key Findings
5.2 Drugs Segment: Market Attractiveness Index
5.3 Geographic Atrophy Market Size Estimation and Forecast by Drugs
5.4 Pegcetacoplan (SYFOVRE)
5.4.1 Market Size by Region, 2025-2035 (US$ Million)
5.4.2 Market Share by Region, 2025 & 2035 (%)
5.5 Avacincaptad pegol (IZERVAY)
5.5.1 Market Size by Region, 2025-2035 (US$ Million)
5.5.2 Market Share by Region, 2025 & 2035 (%)
5.6 Tinlarebant (LBS-008)
5.6.1 Market Size by Region, 2025-2035 (US$ Million)
5.6.2 Market Share by Region, 2025 & 2035 (%)
5.7 Gildeuretinol (ALK-001)
5.7.1 Market Size by Region, 2025-2035 (US$ Million)
5.7.2 Market Share by Region, 2025 & 2035 (%)
5.8 Others
5.8.1 Market Size by Region, 2025-2035 (US$ Million)
5.8.2 Market Share by Region, 2025 & 2035 (%)

6 Geographic Atrophy Market Analysis by Route of Administration

6.1 Key Findings
6.2 Route of Administration Segment: Market Attractiveness Index
6.3 Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
6.4 Intravitreal Route
6.4.1 Market Size by Region, 2025-2035 (US$ Million)
6.4.2 Market Share by Region, 2025 & 2035 (%)
6.5 Intravenous Route
6.5.1 Market Size by Region, 2025-2035 (US$ Million)
6.5.2 Market Share by Region, 2025 & 2035 (%)
6.6 Others
6.6.1 Market Size by Region, 2025-2035 (US$ Million)
6.6.2 Market Share by Region, 2025 & 2035 (%)

7 Geographic Atrophy Market Analysis by Distribution Channel

7.1 Key Findings
7.2 Distribution Channel Segment: Market Attractiveness Index
7.3 Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
7.4 Hospital Pharmacies
7.4.1 Market Size by Region, 2025-2035 (US$ Million)
7.4.2 Market Share by Region, 2025 & 2035 (%)
7.5 Retail Pharmacies
7.5.1 Market Size by Region, 2025-2035 (US$ Million)
7.5.2 Market Share by Region, 2025 & 2035 (%)
7.6 E-Commerce Pharmacies
7.6.1 Market Size by Region, 2025-2035 (US$ Million)
7.6.2 Market Share by Region, 2025 & 2035 (%)

8 Geographic Atrophy Market Analysis by Age Group

8.1 Key Findings
8.2 Age Group Segment: Market Attractiveness Index
8.3 Geographic Atrophy Market Size Estimation and Forecast by Age Group
8.4 Below 60 Years
8.4.1 Market Size by Region, 2025-2035 (US$ Million)
8.4.2 Market Share by Region, 2025 & 2035 (%)
8.5 Above 60 Years
8.5.1 Market Size by Region, 2025-2035 (US$ Million)
8.5.2 Market Share by Region, 2025 & 2035 (%)
8.6 Above 70 Years
8.6.1 Market Size by Region, 2025-2035 (US$ Million)
8.6.2 Market Share by Region, 2025 & 2035 (%)

9 Geographic Atrophy Market Analysis by Region

9.1 Key Findings
9.2 Regional Market Size Estimation and Forecast

10 North America Geographic Atrophy Market Analysis

10.1 Key Findings
10.2 North America Geographic Atrophy Market Attractiveness Index
10.3 North America Geographic Atrophy Market Size by Country, 2025, 2030 & 2035 (US$ Million)
10.4 North America Geographic Atrophy Market Size Estimation and Forecast by Country
10.5 North America Geographic Atrophy Market Size Estimation and Forecast by Type
10.6 North America Geographic Atrophy Market Size Estimation and Forecast by Drugs
10.7 North America Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
10.8 North America Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
10.9 North America Geographic Atrophy Market Size Estimation and Forecast by Age Group
10.10 U.S. Geographic Atrophy Market Analysis
10.11 Canada Geographic Atrophy Market Analysis

11 Europe Geographic Atrophy Market Analysis

11.1 Key Findings
11.2 Europe Geographic Atrophy Market Attractiveness Index
11.3 Europe Geographic Atrophy Market Size by Country, 2025, 2030 & 2035 (US$ Million)
11.4 Europe Geographic Atrophy Market Size Estimation and Forecast by Country
11.5 Europe Geographic Atrophy Market Size Estimation and Forecast by Type
11.6 Europe Geographic Atrophy Market Size Estimation and Forecast by Drugs
11.7 Europe Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
11.8 Europe Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
11.9 Europe Geographic Atrophy Market Size Estimation and Forecast by Age Group
11.10 Germany Geographic Atrophy Market Analysis
11.11 UK Geographic Atrophy Market Analysis
11.12 France Geographic Atrophy Market Analysis
11.13 Italy Geographic Atrophy Market Analysis
11.14 Spain Geographic Atrophy Market Analysis
11.15 Russia Geographic Atrophy Market Analysis
11.16 Netherlands Geographic Atrophy Market Analysis
11.17 Denmark Geographic Atrophy Market Analysis
11.18 Rest of Europe Geographic Atrophy Market Analysis

12 Asia Pacific Geographic Atrophy Market Analysis

12.1 Key Findings
12.2 Asia Pacific Geographic Atrophy Market Attractiveness Index
12.3 Asia Pacific Geographic Atrophy Market Size by Country, 2025, 2030 & 2035 (US$ Million)
12.4 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Country
12.5 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Type
12.6 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Drugs
12.7 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
12.8 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
12.9 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Age Group
12.10 Japan Geographic Atrophy Market Analysis
12.11 China Geographic Atrophy Market Analysis
12.12 India Geographic Atrophy Market Analysis
12.13 Australia Geographic Atrophy Market Analysis
12.14 South Korea Geographic Atrophy Market Analysis
12.15 Rest of Asia Pacific Geographic Atrophy Market Analysis

13 Latin America Geographic Atrophy Market Analysis

13.1 Key Findings
13.2 Latin America Geographic Atrophy Market Attractiveness Index
13.3 Latin America Geographic Atrophy Market Size by Country, 2025, 2030 & 2035 (US$ Million)
13.4 Latin America Geographic Atrophy Market Size Estimation and Forecast by Country
13.5 Latin America Geographic Atrophy Market Size Estimation and Forecast by Type
13.6 Latin America Geographic Atrophy Market Size Estimation and Forecast by Drugs
13.7 Latin America Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
13.8 Latin America Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
13.9 Latin America Geographic Atrophy Market Size Estimation and Forecast by Age Group
13.10 Brazil Geographic Atrophy Market Analysis
13.11 Mexico Geographic Atrophy Market Analysis
13.12 Rest of Latin America Geographic Atrophy Market Analysis

14 MEA Geographic Atrophy Market Analysis

14.1 Key Findings
14.2 MEA Geographic Atrophy Market Attractiveness Index
14.3 MEA Geographic Atrophy Market Size by Country, 2025, 2030 & 2035 (US$ Million)
14.4 MEA Geographic Atrophy Market Size Estimation and Forecast by Country
14.5 MEA Geographic Atrophy Market Size Estimation and Forecast by Type
14.6 MEA Geographic Atrophy Market Size Estimation and Forecast by Drugs
14.7 MEA Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
14.8 MEA Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
14.9 MEA Geographic Atrophy Market Size Estimation and Forecast by Age Group
14.10 GCC Geographic Atrophy Market Analysis
14.11 South Africa Geographic Atrophy Market Analysis
14.12 Rest of MEA Geographic Atrophy Market Analysis

15 Company Profiles

15.1 Competitive Landscape, 2024
15.2 Strategic Outlook
15.1 Alkeus Pharmaceuticals, Inc.
15.1.1 Company Snapshot
15.1.2 Company Overview
15.1.3 Product Benchmarking
15.1.4 Strategic Outlook
15.1.5 SWOT Analysis
15.2 Bausch + Lomb
15.2.1 Company Snapshot
15.2.2 Company Overview
15.2.3 Financial Analysis
15.2.3.1 Net Revenue, 2020-2024
15.2.3.2 R&D, 2020-2024
15.2.3.3 Business Market Shares, 2024
15.2.4 Product Benchmarking
15.2.5 Strategic Outlook
15.2.6 SWOT Analysis
15.3 Ionis Pharmaceuticals
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Financial Analysis
15.3.3.1 Net Revenue, 2020-2024
15.3.3.2 R&D, 2020-2024
15.3.3.3 Business Market Shares, 2024
15.3.4 Product Benchmarking
15.4 Santen Pharmaceutical Co., Ltd.
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Financial Analysis
15.4.3.1 Net Revenue, 2020-2024
15.4.3.2 R&D, 2020-2024
15.4.4 Product Benchmarking
15.4.5 Strategic Outlook
15.5 Astellas Pharma Inc.
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Financial Analysis
15.5.3.1 Net Revenue, 2020-2024
15.5.3.2 R&D, 2020-2024
15.5.3.3 Regional Market Shares, 2024
15.5.3.4 Business Market Shares, 2024
15.5.4 Product Benchmarking
15.5.5 Strategic Outlook
15.5.6 SWOT Analysis
15.6 Boehringer Ingelheim International GmbH
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Financial Analysis
15.6.3.1 Net Revenue, 2020-2024
15.6.3.2 R&D, 2020-2024
15.6.3.3 Regional Market Shares, 2024
15.6.3.4 Business Market Shares, 2024
15.6.4 Product Benchmarking
15.6.5 Strategic Outlook
15.7 F. Hoffmann-La Roche Ltd.
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.3.1 Net Revenue, 2020-2024
15.7.3.2 R&D, 2020-2024
15.7.3.3 Business Market Shares, 2024
15.7.4 Product Benchmarking
15.7.5 Strategic Outlook
15.8 Apellis Pharmaceuticals
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Financial Analysis
15.8.3.1 Net Revenue, 2020-2024
15.8.3.2 R&D, 2020-2024
15.8.3.3 Business Market Shares, 2024
15.8.4 Product Benchmarking
15.8.5 Strategic Outlook
15.8.6 SWOT Analysis
15.9 AstraZeneca
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Financial Analysis
15.9.3.1 Net Revenue, 2020-2024
15.9.3.2 R&D, 2020-2024
15.9.3.3 Regional Market Shares, 2024
15.9.3.4 Business Market Shares, 2024
15.9.4 Product Benchmarking
15.9.5 Strategic Outlook
15.10 Johnson & Johnson
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Financial Analysis
15.10.3.1 Net Revenue, 2020-2024
15.10.3.2 R&D, 2020-2024
15.10.3.3 Regional Market Shares, 2024
15.10.3.4 Business Market Shares, 2024
15.10.4 Product Benchmarking
15.11 Aviceda Therapeutics
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Product Benchmarking
15.11.4 Strategic Outlook
15.12 Annexon, Inc.
15.12.1 Company Snapshot
15.12.2 Company Overview
15.12.3 Financial Analysis
15.12.3.1 R&D, 2020-2024
15.12.4 Product Benchmarking
15.12.5 Strategic Outlook
15.13 Stealth BioTherapeutics Inc.
15.13.1 Company Snapshot
15.13.2 Company Overview
15.13.3 Product Benchmarking
15.13.4 Strategic Outlook
15.14 Belite Bio‚Ñ¢ Inc.
15.14.1 Company Snapshot
15.14.2 Company Overview
15.14.3 Financial Analysis
15.14.3.1 R&D, 2020-2024
15.14.4 Product Benchmarking
15.14.5 Strategic Outlook
15.15 Cognition Therapeutics
15.15.1 Company Snapshot
15.15.2 Company Overview
15.15.3 Financial Analysis
15.15.3.1 R&D, 2020-2024
15.15.4 Product Benchmarking
15.15.5 Strategic Outlook

16 Conclusion and Recommendations

16.1 Concluding Remarks
16.2 Recommendations for Market Players

List of Tables

Table 1 Geographic Atrophy Market Snapshot, 2025 & 2035 (US$ Million, CAGR %)
Table 2 Promising GA Drugs under Clinical Trials, 2025
Table 3 Geographic Atrophy Market: International Trade Tariff Impact Recovery Scenarios Snapshot
Table 4 Geographic Atrophy Market Forecast by Region 2025-2035 (US$ Million, AGR%, CAGR%), Tariff Impact: V- Shaped Recovery Scenario
Table 5 Geographic Atrophy Market Forecast by Region 2025-2035 (US$ Million, AGR%, CAGR%), Tariff Impact: U- Shaped Recovery Scenario
Table 6 Geographic Atrophy Market Forecast by Region 2025-2035 (US$ Million, AGR%, CAGR%), Tariff Impact: L- Shaped Recovery Scenario
Table 7 Geographic Atrophy Market Forecast by Type, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 8 Focal GA Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 9 Multifocal GA Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 10 Confluent GA Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 11 Geographic Atrophy Market Forecast by Drugs, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 12 Pegcetacoplan (SYFOVRE) Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 13 Avacincaptad pegol (IZERVAY) Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 14 Tinlarebant (LBS-008) Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 15 Gildeuretinol (ALK-001) Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 16 Others Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 17 Geographic Atrophy Market Forecast by Route of Administration, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 18 Intravitreal Route Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 19 Intravenous Route Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 20 Others Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 21 Geographic Atrophy Market Forecast by Distribution Channel, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 22 Hospital Pharmacies Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 23 Retail Pharmacies Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 24 E-Commerce Pharmacies Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 25 Geographic Atrophy Market Forecast by Age Group, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 26 Below 60 Years Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 27 Above 60 Years Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 28 Above 70 Years Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 29 Geographic Atrophy Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 30 North America Geographic Atrophy Market Forecast by Country, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 31 North America Geographic Atrophy Market Forecast by Type, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 32 North America Geographic Atrophy Market Forecast by Drugs, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 33 North America Geographic Atrophy Market Forecast by Route of Administration, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 34 North America Geographic Atrophy Market Forecast by Distribution Channel, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 35 North America Geographic Atrophy Market Forecast by Age Group, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 36 U.S. Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 37 Canada Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 38 Europe Geographic Atrophy Market Forecast by Country, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 39 Europe Geographic Atrophy Market Forecast by Type, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 40 Europe Geographic Atrophy Market Forecast by Drugs, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 41 Europe Geographic Atrophy Market Forecast by Route of Administration, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 42 Europe Geographic Atrophy Market Forecast by Distribution Channel, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 43 Europe Geographic Atrophy Market Forecast by Age Group, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 44 Germany Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 45 UK Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 46 France Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 47 Italy Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 48 Spain Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 49 Russia Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 50 Netherlands Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 51 Denmark Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 52 Rest of Europe Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 53 Asia Pacific Geographic Atrophy Market Forecast by Country, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 54 Asia Pacific Geographic Atrophy Market Forecast by Type, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 55 Asia Pacific Geographic Atrophy Market Forecast by Drugs, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 56 Asia Pacific Geographic Atrophy Market Forecast by Route of Administration, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 57 Asia Pacific Geographic Atrophy Market Forecast by Distribution Channel, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 58 Asia Pacific Geographic Atrophy Market Forecast by Age Group, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 59 Japan Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 60 China Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 61 India Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 62 Australia Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 63 South Korea Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 64 Rest of Asia Pacific Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 65 Latin America Geographic Atrophy Market Forecast by Country, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 66 Latin America Geographic Atrophy Market Forecast by Type, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 67 Latin America Geographic Atrophy Market Forecast by Drugs, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 68 Latin America Geographic Atrophy Market Forecast by Route of Administration, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 69 Latin America Geographic Atrophy Market Forecast by Distribution Channel, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 70 Latin America Geographic Atrophy Market Forecast by Age Group, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 71 Brazil Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 72 Mexico Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 73 Rest of Latin America Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 74 MEA Geographic Atrophy Market Forecast by Country, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 75 MEA Geographic Atrophy Market Forecast by Type, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 76 MEA Geographic Atrophy Market Forecast by Drugs, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 77 MEA Geographic Atrophy Market Forecast by Route of Administration, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 78 MEA Geographic Atrophy Market Forecast by Distribution Channel, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 79 MEA Geographic Atrophy Market Forecast by Age Group, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 80 GCC Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 81 South Africa Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 82 Rest of MEA Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR%, CAGR%)
Table 83 Strategic Outlook
Table 84 Alkeus Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 Alkeus Pharmaceuticals, Inc..: Product Benchmarking
Table 86 Alkeus Pharmaceuticals, Inc.: Strategic Outlook
Table 87 Alkeus Pharmaceuticals, Inc.: SWOT Analysis
Table 88 Bausch + Lomb: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 Bausch + Lomb: Product Benchmarking
Table 90 Bausch + Lomb: Strategic Outlook
Table 91 Bausch + Lomb: SWOT Analysis
Table 92 Ionis Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 Ionis Pharmaceuticals: Product Benchmarking
Table 94 Santen Pharmaceutical Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 95 Santen Pharmaceutical Co., Ltd.: Product Benchmarking
Table 96 Santen Pharmaceutical Co., Ltd.: Strategic Outlook
Table 97 Astellas Pharma Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 Astellas Pharma Inc.: Product Benchmarking
Table 99 Astellas Pharma Inc.: Strategic Outlook
Table 100 Astellas Pharma Inc.: SWOT Analysis
Table 101 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Boehringer Ingelheim International GmbH: Product Benchmarking
Table 103 Boehringer Ingelheim International GmbH: Strategic Outlook
Table 104 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 F. Hoffmann-La Roche Ltd.: Product Benchmarking
Table 106 F. Hoffmann-La Roche Ltd.: Strategic Outlook
Table 107 Apellis Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 Apellis Pharmaceuticals: Product Benchmarking
Table 109 Apellis Pharmaceuticals: Strategic Outlook
Table 110 Apellis Pharmaceuticals: SWOT Analysis
Table 111 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 112 AstraZeneca: Product Benchmarking
Table 113 AstraZeneca: Strategic Outlook
Table 114 Johnson & Johnson: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 Johnson & Johnson: Product Benchmarking
Table 116 Aviceda Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 117 Aviceda Therapeutics: Product Benchmarking
Table 118 Aviceda Therapeutics: Strategic Outlook
Table 119 Annexon, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 120 Annexon, Inc.: Product Benchmarking
Table 121 Annexon, Inc.: Strategic Outlook
Table 122 Stealth BioTherapeutics Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 123 Stealth BioTherapeutics Inc.: Product Benchmarking
Table 124 Stealth BioTherapeutics Inc. Inc.: Strategic Outlook
Table 125 Belite Bio‚Ñ¢ Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 126 Belite Bio‚Ñ¢ Inc.: Product Benchmarking
Table 127 Belite Bio‚Ñ¢ Inc.: Strategic Outlook
Table 128 Cognition Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 129 Cognition Therapeutics: Product Benchmarking
Table 130 Cognition Therapeutics: Strategic Outlook

List of Figures

Figure 1 Geographic Atrophy Market Segmentation
Figure 2 Geographic Atrophy Market by Type: Market Attractiveness Index
Figure 3 Geographic Atrophy Market by Drugs: Market Attractiveness Index
Figure 4 Geographic Atrophy Market by Route of Administration: Market Attractiveness Index
Figure 5 Geographic Atrophy Market by Distribution Channel: Market Attractiveness Index
Figure 6 Geographic Atrophy Market by Age Group: Market Attractiveness Index
Figure 7 Geographic Atrophy Market Attractiveness Index by Region
Figure 8 Geographic Atrophy Market: Market Dynamics
Figure 9 Geographic Atrophy Market: Impact Analysis
Figure 1 Geographic Atrophy Market by Region, 2025-2035 (US$ Million, AGR %), Tariff Impact: V-Shaped Recovery Scenario
Figure 2 Geographic Atrophy Market by Region, 2025-2035 (US$ Million, AGR %), Tariff Impact: U-Shaped Recovery Scenario
Figure 3 Geographic Atrophy Market by Region, 2025-2035 (US$ Million, AGR %), Tariff Impact: L-Shaped Recovery Scenario
Figure 4 Short-term & Long-term Planning
Figure 5 Impact of U.S. and China Trade War
Figure 10 Geographic Atrophy Market: Porter's Five Forces Analysis
Figure 11 Geographic Atrophy Market: PEST Analysis
Figure 12 Geographic Atrophy Market Attractiveness Index by Type
Figure 13 Geographic Atrophy Market Forecast by Type, 2025-2035 (US$ Million, AGR %)
Figure 14 Geographic Atrophy Market Share Forecast by Type, 2025, 2030, 2035 (%)
Figure 15 Focal GA Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 16 Focal GA Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 17 Multifocal GA Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 18 Multifocal GA Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 19 Confluent GA Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 20 Confluent GA Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 21 Geographic Atrophy Market Attractiveness Index by Drugs
Figure 22 Geographic Atrophy Market Forecast by Drugs, 2025-2035 (US$ Million, AGR %)
Figure 23 Geographic Atrophy Market Share Forecast by Drugs, 2025, 2030, 2035 (%)
Figure 24 Pegcetacoplan (SYFOVRE) Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 25 Pegcetacoplan (SYFOVRE) Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 26 Avacincaptad pegol (IZERVAY) Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 27 Avacincaptad pegol (IZERVAY) Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 28 Tinlarebant (LBS-008) Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 29 Tinlarebant (LBS-008) Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 30 Gildeuretinol (ALK-001) Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 31 Gildeuretinol (ALK-001) Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 32 Others Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 33 Others Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 34 Geographic Atrophy Market by Route of Administration: Market Attractiveness Index
Figure 35 Geographic Atrophy Market Forecast by Route of Administration, 2025-2035 (US$ Million, AGR %)
Figure 36 Geographic Atrophy Share Forecast by Route of Administration, 2025, 2030, 2035 (%)
Figure 37 Intravitreal Route Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 38 Intravitreal Route Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 39 Intravenous Route Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 40 Intravenous Route Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 41 Others Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 42 Others Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 43 Geographic Atrophy Market by Distribution Channel: Market Attractiveness Index
Figure 44 Geographic Atrophy Market Forecast by Distribution Channel, 2025-2035 (US$ Million, AGR %)
Figure 45 Geographic Atrophy Share Forecast by Distribution Channel, 2025, 2030, 2035 (%)
Figure 46 Hospital Pharmacies Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 47 Hospital Pharmacies Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 48 Retail Pharmacies Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 49 Retail Pharmacies Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 50 E-Commerce Pharmacies Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 51 E-Commerce Pharmacies Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 52 Geographic Atrophy Market Attractiveness Index by Age Group
Figure 53 Geographic Atrophy Market Forecast by Age Group, 2025-2035 (US$ Million, AGR %)
Figure 54 Geographic Atrophy Market Share Forecast by Age Group, 2025, 2030, 2035 (%)
Figure 55 Below 60 Years Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 56 Below 60 Years Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 57 Above 60 Years Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 58 Above 60 Years Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 59 Above 70 Years Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 60 Above 70 Years Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 61 Geographic Atrophy Market Forecast by Region 2025 & 2035 (Revenue, CAGR%)
Figure 62 Geographic Atrophy Market by Region, 2025-2035 (US$ Million)
Figure 63 Geographic Atrophy Market Share Forecast by Region 2025, 2030, 2035 (%)
Figure 64 North America Geographic Atrophy Market Attractiveness Index
Figure 65 North America Geographic Atrophy Market by Region, 2025, 2030 & 2035 (US$ Million)
Figure 66 North America Geographic Atrophy Market Forecast by Country, 2025-2035 (US$ million)
Figure 67 North America Geographic Atrophy Market Share Forecast by Country, 2025 & 2035 (%)
Figure 68 North America Geographic Atrophy Market Forecast by Type, 2025-2035 (US$ Million, AGR %)
Figure 69 North America Geographic Atrophy Market Share Forecast by Type, 2025 & 2035 (%)
Figure 70 North America Geographic Atrophy Market Forecast by Drugs, 2025-2035 (US$ Million, AGR %)
Figure 71 North America Geographic Atrophy Market Share Forecast by Drugs, 2025 & 2035 (%)
Figure 72 North America Geographic Atrophy Market Forecast by Route of Administration, 2025-2035 (US$ Million, AGR %)
Figure 73 North America Geographic Atrophy Market Share Forecast by Route of Administration, 2025 & 2035 (%)
Figure 74 North America Geographic Atrophy Market Forecast by Distribution Channel, 2025-2035 (US$ Million, AGR %)
Figure 75 North America Geographic Atrophy Market Share Forecast by Distribution Channel, 2025 & 2035 (%)
Figure 76 North America Geographic Atrophy Market Forecast by Age Group, 2025-2035 (US$ Million, AGR %)
Figure 77 North America Geographic Atrophy Market Share Forecast by Age Group, 2025 & 2035 (%)
Figure 78 U.S. Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 79 Canada Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 80 Europe Geographic Atrophy Market Attractiveness Index
Figure 81 Europe Geographic Atrophy Market by Region, 2025, 2030 & 2035 (US$ Million)
Figure 82 Europe Geographic Atrophy Market Forecast by Country, 2025-2035 (US$ million)
Figure 83 Europe Geographic Atrophy Market Share Forecast by Country, 2025 & 2035 (%)
Figure 84 Europe Geographic Atrophy Market Forecast by Type, 2025-2035 (US$ Million, AGR %)
Figure 85 Europe Geographic Atrophy Market Share Forecast by Type, 2025 & 2035 (%)
Figure 86 Europe Geographic Atrophy Market Forecast by Drugs, 2025-2035 (US$ Million, AGR %)
Figure 87 Europe Geographic Atrophy Market Share Forecast by Drugs, 2025 & 2035 (%)
Figure 88 Europe Geographic Atrophy Market Forecast by Route of Administration, 2025-2035 (US$ Million, AGR %)
Figure 89 Europe Geographic Atrophy Market Share Forecast by Route of Administration, 2025 & 2035 (%)
Figure 90 Europe Geographic Atrophy Market Forecast by Distribution Channel, 2025-2035 (US$ Million, AGR %)
Figure 91 Europe Geographic Atrophy Market Share Forecast by Distribution Channel, 2025 & 2035 (%)
Figure 92 Europe Geographic Atrophy Market Forecast by Age Group, 2025-2035 (US$ Million, AGR %)
Figure 93 Europe Geographic Atrophy Market Share Forecast by Age Group, 2025 & 2035 (%)
Figure 94 Germany Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 95 UK Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 96 France Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 97 Italy Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 98 Spain Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 99 Russia Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 100 Netherlands Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 101 Denmark Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 102 Rest of Europe Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 103 Asia Pacific Geographic Atrophy Market Attractiveness Index
Figure 104 Asia Pacific Geographic Atrophy Market by Region, 2025, 2030 & 2035 (US$ Million)
Figure 105 Asia Pacific Geographic Atrophy Market Forecast by Country, 2025-2035 (US$ Million)
Figure 106 Asia Pacific Geographic Atrophy Market Share Forecast by Country, 2025 & 2035 (%)
Figure 107 Asia Pacific Geographic Atrophy Market Forecast by Type, 2025-2035 (US$ Million, AGR %)
Figure 108 Asia Pacific Geographic Atrophy Market Share Forecast by Type, 2025 & 2035 (%)
Figure 109 Asia Pacific Geographic Atrophy Market Forecast by Drugs, 2025-2035 (US$ Million, AGR %)
Figure 110 Asia Pacific Geographic Atrophy Market Share Forecast by Drugs, 2025 & 2035 (%)
Figure 111 Asia Pacific Geographic Atrophy Market Forecast by Route of Administration, 2025-2035 (US$ Million, AGR %)
Figure 112 Asia Pacific Geographic Atrophy Market Share Forecast by Route of Administration, 2025 & 2035 (%)
Figure 113 Asia Pacific Geographic Atrophy Market Forecast by Distribution Channel, 2025-2035 (US$ Million, AGR %)
Figure 114 Asia Pacific Geographic Atrophy Market Share Forecast by Distribution Channel, 2025 & 2035 (%)
Figure 115 Asia Pacific Geographic Atrophy Market Forecast by Age Group, 2025-2035 (US$ Million, AGR %)
Figure 116 Asia Pacific Geographic Atrophy Market Share Forecast by Age Group, 2025 & 2035 (%)
Figure 117 Japan Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 118 China Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 119 India Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 120 Australia Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 121 South Korea Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 122 Rest of Asia Pacific Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 123 Latin America Geographic Atrophy Market Attractiveness Index
Figure 124 Latin America Geographic Atrophy Market by Region, 2025, 2030 & 2035 (US$ Million)
Figure 125 Latin America Geographic Atrophy Market Forecast by Country, 2025-2035 (US$ million)
Figure 126 Latin America Geographic Atrophy Market Share Forecast by Country, 2025 & 2035 (%)
Figure 127 Latin America Geographic Atrophy Market Forecast by Type, 2025-2035 (US$ Million, AGR %)
Figure 128 Latin America Geographic Atrophy Market Share Forecast by Type, 2025 & 2035 (%)
Figure 129 Latin America Geographic Atrophy Market Forecast by Drugs, 2025-2035 (US$ Million, AGR %)
Figure 130 Latin America Geographic Atrophy Market Share Forecast by Drugs, 2025 & 2035 (%)
Figure 131 Latin America Geographic Atrophy Market Forecast by Route of Administration, 2025-2035 (US$ Million, AGR %)
Figure 132 Latin America Geographic Atrophy Market Share Forecast by Route of Administration, 2025 & 2035 (%)
Figure 133 Latin America Geographic Atrophy Market Forecast by Distribution Channel, 2025-2035 (US$ Million, AGR %)
Figure 134 Latin America Geographic Atrophy Market Share Forecast by Distribution Channel, 2025 & 2035 (%)
Figure 135 Latin America Geographic Atrophy Market Forecast by Age Group, 2025-2035 (US$ Million, AGR %)
Figure 136 Latin America Geographic Atrophy Market Share Forecast by Age Group, 2025 & 2035 (%)
Figure 137 Brazil Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 138 Mexico Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 139 Rest of Latin America Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 140 MEA Geographic Atrophy Market Attractiveness Index
Figure 141 MEA Geographic Atrophy Market by Region, 2025, 2030 & 2035 (US$ Million)
Figure 142 MEA Geographic Atrophy Market Forecast by Country, 2025-2035 (US$ million)
Figure 143 MEA Geographic Atrophy Market Share Forecast by Country, 2025 & 2035 (%)
Figure 144 MEA Geographic Atrophy Market Forecast by Type, 2025-2035 (US$ Million, AGR %)
Figure 145 MEA Geographic Atrophy Market Share Forecast by Type, 2025 & 2035 (%)
Figure 146 MEA Geographic Atrophy Market Forecast by Drugs, 2025-2035 (US$ Million, AGR %)
Figure 147 MEA Geographic Atrophy Market Share Forecast by Drugs, 2025 & 2035 (%)
Figure 148 MEA Geographic Atrophy Market Forecast by Route of Administration, 2025-2035 (US$ Million, AGR %)
Figure 149 MEA Geographic Atrophy Market Share Forecast by Route of Administration, 2025 & 2035 (%)
Figure 150 MEA Geographic Atrophy Market Forecast by Distribution Channel, 2025-2035 (US$ Million, AGR %)
Figure 151 MEA Geographic Atrophy Market Share Forecast by Distribution Channel, 2025 & 2035 (%)
Figure 152 MEA Geographic Atrophy Market Forecast by Age Group, 2025-2035 (US$ Million, AGR %)
Figure 153 MEA Geographic Atrophy Market Share Forecast by Age Group, 2025 & 2035 (%)
Figure 154 GCC Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 155 South Africa Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 156 Rest of MEA Geographic Atrophy Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 157 Geographic Atrophy Market: Company Share, 2024
Figure 158 Bausch + Lomb: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 159 Bausch + Lomb: R&D, 2020-2024 (US$ Million, AGR%)
Figure 160 Bausch + Lomb: Business Market Shares, 2024
Figure 161 Ionis Pharmaceuticals: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 162 Ionis Pharmaceuticals: R&D, 2020-2024 (US$ Million, AGR%)
Figure 163 Ionis Pharmaceuticals: Business Market Shares, 2024
Figure 164 Santen Pharmaceutical Co., Ltd.: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 165 Santen Pharmaceutical Co., Ltd.: R&D, 2020-2024 (US$ Million, AGR%)
Figure 166 Astellas Pharma Inc.: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 167 Astellas Pharma Inc.: R&D, 2020-2024 (US$ Million, AGR%)
Figure 168 Astellas Pharma Inc.: Regional Market Shares, 2024
Figure 169 Astellas Pharma Inc.: Business Market Shares, 2024
Figure 170 Boehringer Ingelheim International GmbH: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 171 Boehringer Ingelheim International GmbH: R&D, 2020-2024 (US$ Million, AGR%)
Figure 172 Boehringer Ingelheim International GmbH: Regional Market Shares, 2024
Figure 173 Boehringer Ingelheim International GmbH: Business Market Shares, 2024
Figure 174 F. Hoffmann-La Roche Ltd.: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 175 F. Hoffmann-La Roche Ltd.: R&D, 2020-2024 (US$ Million, AGR%)
Figure 176 F. Hoffmann-La Roche Ltd.: Business Market Shares, 2024
Figure 177 Apellis Pharmaceuticals: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 178 Apellis Pharmaceuticals: R&D, 2020-2024 (US$ Million, AGR%)
Figure 179 Apellis Pharmaceuticals: Business Market Shares, 2024
Figure 180 AstraZeneca: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 181 AstraZeneca: R&D, 2020-2024 (US$ Million, AGR%)
Figure 182 AstraZeneca: Regional Market Shares, 2024
Figure 183 AstraZeneca: Business Market Shares, 2024
Figure 184 Johnson & Johnson: Net Revenue, 2020-2024 (US$ Million, AGR%)
Figure 185 Johnson & Johnson: R&D, 2020-2024 (US$ Million, AGR%)
Figure 186 Johnson & Johnson: Regional Market Shares, 2024
Figure 187 Johnson & Johnson: Business Market Shares, 2024
Figure 188 Annexon, Inc.: R&D, 2020-2024 (US$ Million, AGR%)
Figure 189 Belite Bio™ Inc.: R&D, 2020-2024 (US$ Million, AGR%)
Figure 190 Cognition Therapeutics: R&D, 2020-2024 (US$ Million, AGR%)

Companies Mentioned

Alkeus Pharmaceuticals, Inc.
Annexon, Inc.
Apellis Pharmaceuticals
Astellas Pharma Inc.
AstraZeneca
Aviceda Therapeutics
Bausch + Lomb
Belite Bio‚Ñ¢ Inc.
Boehringer Ingelheim International GmbH
Cognition Therapeutics
F. Hoffmann-La Roche Ltd.
Ionis Pharmaceuticals
Johnson & Johnson
Santen Pharmaceutical Co., Ltd.
Stealth BioTherapeutics
Amazon
AMD-Netz
Bayer
Bayer Yakuhin, Ltd.
CDR-Life Inc.
City Tx
CSPC Pharmaceuticals Group Limited
Eyestem Research
Genentech
Lineage Cell
Genetech
Gyroscope Therapeutics
Inflammasome Therapeutics
Iveric Bio
Mitsubishi Research Institute, Inc.
Modulight Corporation
Novartis
Novartis Canada
ProRetina
RetinAI
Roche Canada
Whitecap Biosciences, LLC
American Academy of Ophthalmology
ANVISA
AVE
CBRE
Center for Drug Evaluation (CDE)
Center for Drug Evaluation and Research / Center for Biologics Evaluation and Research
Central Drugs Standard Control Organisation (CDSCO)
Comitato Macula
Committee for Medicinal Types for Human Use (CHMP)
Danish Medical Journal
Digital Media Licensing Association (DMLA)
European Medicines Agency (EMA)
European Union (EU) and the European Economic Area (EEA)
FDA
French Health Authority
German Ophthalmological Society (DOG)
Health Canada
International Agency for the Prevention of Blindness (IAPB)
International Council for Harmonisation (ICH)
Italian Association of Ophthalmologists (AIMO)
Italian Society of Ophthalmology (SOI)
Italian Union of the Blind (UICI)
Journal of the American Medical Association (JAMA)
Macula Retina Association (Asociaci√≥n M√°cula Retina)
Medicines and Healthcare products Regulatory Agency (MHRA)
Ministry of Food and Drug Safety (MFDS)
Ministry of Health, Italy
Ministry of Health, Labour and Welfare (MHLW)
Moorfields Eye Hospital and University College London
National Institutes of Health (NIH)
National Medical Products Administration (NMPA)
NCBI
Pharmaceuticals and Medical Devices Agency (PMDA)
Retina Italia ODV
Societ√† Italiana di Scienze Oftalmologiche (S.I.S.O.)
Spanish National Organization of the Blind (Organizaci√≥n Nacional de Ciegos Espa√±oles - ONCE)
Therapeutic Goods Administration (TGA)
U.S. Food and Drug Administration
United Nations (UN)
University of Cologne
University of Toronto
World Health Organisation (WHO)

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5205EUR$6,103USD£4,350GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€6162EUR$7,225USD£5,150GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7239EUR$8,487USD£6,050GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€9147EUR$10,725USD£7,645GBP